Company research
KALA BIO, Inc.
CIK 1479419Updated Nov 13, 2026
SecurityKALA · NASDAQ · equity
Name history
KALA BIO, Inc. · through Nov 12, 2026Kala Pharmaceuticals, Inc. · through Jun 23, 2023
KALA price & chart
Loading TradingView…
NASDAQ:KALA on TradingView ↗About the company
KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline - including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates - with a scalable AI platform-as-a-service business that deploys secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments. Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of inno…
In the news
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency” ↗
Seeking Alpha
Kala Bio rises on plans to leverage AI ↗
Recent filings
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Items 3.03, 5.03, 8.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
DEF 14A filing
PRE 14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 25,021,000Source | 54,079,000Source | 10,582,000Source | 36,053,000Source | 61,606,000Source | 12,318,000Source | 48,252,000Source | 53,033,000Source | 9,490,000Source | 55,483,000Source | 55,949,000Source | 86,820,000Source |
| Property, Plant and EquipmentUSD | 603,000Source | 762,000Source | — | 657,000Source | 617,000Source | — | 695,000Source | 714,000Source | — | 749,000Source | 753,000Source | 400,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 21,096,000Source | 49,202,000Source | 229,000Source | 31,942,000Source | 54,197,000Source | 1,764,000Source | 42,222,000Source | 48,478,000Source | 7,557,000Source | 51,181,000Source | 50,895,000Source | 70,495,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 195,000Source |
| Assets, CurrentUSD | 24,274,000Source | 51,279,000Source | 10,582,000Source | 33,663,000Source | 58,853,000Source | 12,318,000Source | 45,717,000Source | 50,087,000Source | 9,490,000Source | 52,797,000Source | 52,870,000Source | 85,942,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,178,000Source | 2,077,000Source | 3,353,000Source | 1,721,000Source | 4,656,000Source | 3,554,000Source | 3,495,000Source | 1,609,000Source | 1,933,000Source | 1,616,000Source | 1,975,000Source | 7,657,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 1,778,000Source | — | 1,507,000Source | 1,863,000Source | — | 1,601,000Source | 1,945,000Source | — | 1,691,000Source | 2,025,000Source | 16,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 33,686,000Source | 47,220,000Source | 1,538,000Source | 39,259,000Source | 47,889,000Source | 1,557,000Source | 42,544,000Source | 46,372,000Source | 2,494,000Source | 43,151,000Source | 48,445,000Source | 67,846,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | 1,000Source | — | — | 1,000Source | — | — | — |
| Common Stock, Value, IssuedUSD | 7,000Source | 5,000Source | 20,000Source | 7,000Source | 5,000Source | 19,000Source | 6,000Source | 3,000Source | 28,000Source | 6,000Source | 3,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 686,914,000Source | 666,599,000Source | 707,126,000Source | 684,809,000Source | 664,507,000Source | 707,262,000Source | 682,569,000Source | 647,874,000Source | 701,867,000Source | 680,246,000Source | 636,910,000Source | 606,182,000Source |
| Retained Earnings (Accumulated Deficit)USD | -695,586,000Source | -659,745,000Source | -698,102,000Source | -688,022,000Source | -650,795,000Source | -696,521,000Source | -676,867,000Source | -641,216,000Source | -694,900,000Source | -667,920,000Source | -629,409,000Source | -587,210,000Source |
| Stockholders' Equity Attributable to ParentUSD | -8,665,000Source | 6,859,000Source | 9,044,000Source | -3,206,000Source | 13,717,000Source | 10,761,000Source | 5,708,000Source | 6,661,000Source | 6,996,000Source | 12,332,000Source | 7,504,000Source | 18,974,000Source |
| Liabilities and EquityUSD | 25,021,000Source | 54,079,000Source | 10,582,000Source | 36,053,000Source | 61,606,000Source | 12,318,000Source | 48,252,000Source | 53,033,000Source | 9,490,000Source | 55,483,000Source | 55,949,000Source | 86,820,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 32,574,000Source | 23,867,000Source | 1,538,000Source | 16,016,000Source | 19,190,000Source | 1,557,000Source | 22,975,000Source | 11,879,000Source | 2,494,000Source | 16,956,000Source | 8,346,000Source | 25,685,000Source |
| Operating Lease, Liability, CurrentUSD | 420,000Source | 368,000Source | — | 406,000Source | 356,000Source | — | 393,000Source | 345,000Source | — | 380,000Source | 334,000Source | 13,000Source |
| Accounts Payable, CurrentUSD | 917,000Source | 711,000Source | 1,142,000Source | 658,000Source | 665,000Source | 1,044,000Source | 931,000Source | 732,000Source | 986,000Source | 628,000Source | 919,000Source | 2,832,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,112,000Source | 1,532,000Source | — | 1,227,000Source | 1,628,000Source | — | 1,332,000Source | 1,715,000Source | — | 1,434,000Source | 1,799,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 4,497,000Source | — | — | 3,924,000Source | — | — | 4,810,000Source | — | — | 6,018,000Source | 8,910,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 4,189,000Source |
| Long-term Debt, Current MaturitiesUSD | 28,411,000Source | 17,977,000Source | — | 9,511,000Source | 11,985,000Source | — | 15,503,000Source | 5,992,000Source | — | 10,336,000Source | — | 5,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 17,162,000Source | — | 18,786,000Source | 22,832,000Source | — | 15,121,000Source | 28,510,000Source | — | 20,102,000Source | 34,190,000Source | 37,937,000Source |
| Long-term Debt | —Source | —Source | — | —Source | —Source | — | —Source | —Source | — | — | — | — |
| Short-term Investments | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -1,621,000Source | -8,947,000Source | -26,980,000Source | -38,511,000Source | -42,199,000Source | -44,822,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | 68,000Source | 317,000Source | 259,000Source | 303,000Source | 537,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | -471,000Source | 2,310,000Source | 6,995,000Source | 8,389,000Source | 7,463,000Source | 7,008,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | -78,000Source | -15,138,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | — | — | -7,544,000Source | -1,708,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 58,000Source | 303,000Source | 358,000Source | -291,000Source | -1,904,000Source | -2,076,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,895,000Source | -8,824,000Source | -31,991,000Source | -29,382,000Source | -27,927,000Source | -78,908,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -7,000,000Source | — | -15,000Source | -208,000Source | -429,000Source | 62,717,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 4,102,000Source | -135,000Source | -11,618,000Source | 29,876,000Source | 8,506,000Source | -7,942,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -5,793,000Source | -8,959,000Source | -43,624,000Source | 286,000Source | -19,850,000Source | -24,133,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 909,000Source | 2,701,000Source | 4,610,000Source | 4,620,000Source | 5,958,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,044,000Source | 2,036,000Source | -136,000Source | 2,240,000Source | -471,000Source | 2,310,000Source | 6,995,000Source | 8,389,000Source | 7,463,000Source | 7,008,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | 186,000Source | -667,000Source | 1,248,000Source | 1,253,000Source | 1,425,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 216,000Source | 204,000Source | 248,000Source | 421,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | — | — | — | — | — | 46,995,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -549,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 5,793,000Source | — | — | -2,583,000Source |
| General and Administrative ExpenseUSD | — | — | 4,534,000Source | 4,400,000Source | 1,662,000Source | 4,643,000Source | 1,741,000Source | 4,593,000Source | 23,629,000Source | 18,340,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 963,000Source | 1,478,000Source | — | 1,081,000Source | — | 1,091,000Source | 3,276,000Source | 5,783,000Source | — | — |
| Investment Income, InterestUSD | — | — | 270,000Source | 570,000Source | 140,000Source | 407,000Source | 74,000Source | 463,000Source | 1,140,000Source | 2,056,000Source | 2,711,000Source | 664,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,564,000Source | -8,950,000Source | -1,581,000Source | -11,155,000Source | -1,621,000Source | -8,947,000Source | -26,980,000Source | -38,511,000Source | -42,199,000Source | -44,822,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,564,000Source | -8,950,000Source | -1,581,000Source | -11,155,000Source | -1,621,000Source | -8,947,000Source | -26,980,000Source | -38,511,000Source | -42,199,000Source | -44,822,000Source |
| Nonoperating Income (Expense)USD | — | — | -325,000Source | 1,038,000Source | 140,000Source | -127,000Source | 181,000Source | 1,722,000Source | 12,181,000Source | 2,472,000Source | -2,536,000Source | 36,884,000Source |
| Operating ExpensesUSD | — | — | 7,239,000Source | 9,988,000Source | 1,721,000Source | 11,028,000Source | 1,802,000Source | 10,669,000Source | 39,161,000Source | 40,983,000Source | 39,663,000Source | 85,598,000Source |
| Operating Lease, Impairment LossUSD | — | — | 1,411,000Source | — | — | — | — | — | 1,411,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -112,000Source | — | — | — | 107,000Source | — | 5,147,000Source | — | -4,258,000Source | -926,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 9,134,000Source | 3,394,000Source | 18,536,000Source | 1,036,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 3,892,000Source |
| Restructuring Costs | — | — | —Source | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 20,567,000Source | 65,035,000Source |
| Operating Income (Loss)USD | — | — | -7,239,000Source | -9,988,000Source | -1,721,000Source | -11,028,000Source | -1,802,000Source | -10,669,000Source | -39,161,000Source | -40,983,000Source | -39,663,000Source | -81,706,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -112,000Source | — | — | — | 107,000Source | — | 5,147,000Source | — | -4,258,000Source | -926,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,564,000Source | -8,950,000Source | -1,581,000Source | -11,155,000Source | -1,621,000Source | -8,947,000Source | -26,980,000Source | -38,511,000Source | -42,199,000Source | -44,822,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | -21.32Source | -85.64Source | -0.14Source | -70.49Source | -3.31Source | -10.15Source | -17.35Source | -29.48Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | -21.32Source | -85.64Source | -0.14Source | -70.49Source | -3.31Source | -10.15Source | -17.35Source | -29.48Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 74,159Source | 130,262Source | 11,873,568Source | 126,917Source | 8,148,275Source | 3,796,047Source | 2,432,008Source | 1,520,611Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 74,159Source | 130,262Source | 11,873,568Source | 126,917Source | 8,148,275Source | 3,796,047Source | 2,432,008Source | 1,520,611Source |
| Interest Expense (non-operating)USD | — | — | 963,000Source | 1,478,000Source | — | 1,081,000Source | — | 1,091,000Source | 3,276,000Source | 5,783,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 4,534,000Source | 4,400,000Source | 1,662,000Source | 4,643,000Source | 1,741,000Source | 4,593,000Source | 23,629,000Source | 18,340,000Source | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 5,814,000Source | 7,266,000Source |
| Investment Income, InterestUSD | — | — | 270,000Source | 570,000Source | 140,000Source | 407,000Source | 74,000Source | 463,000Source | 1,140,000Source | 2,056,000Source | 2,711,000Source | 664,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,564,000Source | -8,950,000Source | -1,581,000Source | -11,155,000Source | -1,621,000Source | -8,947,000Source | -26,980,000Source | -38,511,000Source | -42,199,000Source | -44,822,000Source |
| Nonoperating Income (Expense)USD | — | — | -325,000Source | 1,038,000Source | 140,000Source | -127,000Source | 181,000Source | 1,722,000Source | 12,181,000Source | 2,472,000Source | -2,536,000Source | 36,884,000Source |
| Operating ExpensesUSD | — | — | 7,239,000Source | 9,988,000Source | 1,721,000Source | 11,028,000Source | 1,802,000Source | 10,669,000Source | 39,161,000Source | 40,983,000Source | 39,663,000Source | 85,598,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 3,892,000Source |
| Research and Development Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Restructuring Costs | — | — | —Source | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-295667
Registration 333-293323
Filing attachments
kalabio_ex99-1.htm · 8-K · 2026-11-12
Exhibit 99.1 KALA BIO Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on November 16, 2026 Arlington, MA, November 12, 2026 (GLOBE NEWSWIRE) - KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m.…
Read attachment ↗kalabio_ex99-1.htm · 8-K · 2026-11-09
Exhibit 99.1 KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results New York, November 9, 2026 - KALA BIO, Inc. (Nasdaq: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026. Preliminary Third Quarter 2026 Results Net loss of approximately $0.8 million for the third quarter of 2026, compared to $7.6 million for the third quarter of 2025. Net loss of approximately $4.0 million for the nine months ended Sep…
Read attachment ↗kalabio_ex4-1.htm · S-3/A · 2026-06-12
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of KALA BIO, Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our certificate of incorporation, our bylaws and applicable provisions of the Delaware General Corporate Law (the “DGCL”). You should read our c…
Read attachment ↗kalabio_ex107.htm · S-3 · 2026-05-07
Exhibit 107 Calculation of Filing Fee Tables S-3 N/A KALA BIO, Inc. Table 1: Newly Registered and Carry Forward Securities ☐ Not Applicable ──────────────────────────────────────────────────────────────────────────────── Security Security Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price …
Read attachment ↗kalabio_ex4-1.htm · S-3 · 2026-05-07
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of KALA BIO, Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our certificate of incorporation, our bylaws and applicable provisions of the Delaware General Corporate Law (the “DGCL”). You should read our c…
Read attachment ↗kalabio_ex4-5.htm · S-3 · 2026-05-07
Exhibit 4.5 KALA BIO, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture ──────────────────────────────────────────────────────────────────────── 310(a). 7.09 310(b). 7.08 7.10 310(c). …
Read attachment ↗